24/7 Market News Snapshot 23 August, 2024 – SciSparc Ltd. Ordinary Shares (NASDAQ:SPRC)

August 23, 2024

DENVER, Colo., 23 August, 2024 (247marketnews.com) – (NASDAQ:SPRC) are discussed in this article.
SciSparc Ltd. (NASDAQ:SPRC) has made significant strides in its market position and therapeutic development efforts. After starting the trading session at $0.37 and experiencing an initial decline of approximately 4.02%, the stock rebounded, reaching a price of $0.494. This volatility, evidenced by a current trading volume of 6.55 million shares, highlights robust investor engagement and suggests that stakeholders should closely monitor pricing trends for potential support and resistance levels.

In addition to its market activity, SciSparc has announced a critical advancement in its clinical research portfolio. The company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its proposed Phase IIb clinical trial of SCI-110, a proprietary drug aimed at treating Tourette Syndrome (TS). This milestone represents a collective effort by SciSparc’s team and collaboration with prominent researchers.

The Phase IIb trial will take place at three highly regarded medical centers, each selected for its expertise in clinical research. These sites include a leading child study center, a prestigious international medical school, and a respected medical center known for comprehensive patient care. All trial locations have obtained necessary approvals from relevant Institutional Review Boards and regulatory bodies.

The primary objective of this clinical trial is to evaluate the efficacy, safety, and tolerability of SCI-110, a unique formulation combining dronabinol and palmitoylethanolamide. Adult participants will be randomly assigned to receive either the investigational drug or a matched placebo, with tic severity assessed at 12 and 26 weeks using the Yale Global Tic Severity Scale.

Through these endeavors, SciSparc demonstrates a strong commitment to addressing the unmet medical needs of patients with TS and advancing cannabinoid-based therapeutic solutions. The promising implications of SCI-110 highlight the company’s dedication to innovation in the healthcare sector, paving the way for potential breakthroughs in treatment.

Related news for (SPRC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.